Metastatic Cancer clinical trials at UC Irvine

• Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL 2

  open to eligible people ages 18 years and up

  This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

  Orange, California and other locations

• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

  open to eligible people ages 18 years and up

  This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

  Orange, California and other locations

• Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

  open to eligible people ages 18-100

  This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).

  Orange, California

Last updated: July 20, 2021